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Abstract
Bisphosphonates, besides being important drugs for the treatment of various bone diseases, could also be used to induce
apoptosis in macrophage-like and cancer cells. However, their activity in vivo is limited by a short plasma half-life and rapid
uptake within bone. Therefore, several delivery systems have been proposed to modify their pharmacokinetic profile and
biodistribution. Among these, red blood cells (RBCs) represent one of the most promising biological carriers. The aim of this
study was to select the best performing compound among Clodronate, Pamidronate, Ibandronate and Zoledronate in
killing macrophages and to investigate RBCs as innovative carrier system to selectively target bisphosphonates to
macrophages. To this end, the encapsulation of the selected bisphosphonates in autologous RBCs as well as the effect on
macrophages, both in vitro and in vivo were studied. This work shows that, among the tested bisphosphonates,
Zoledronate has proven to be the most active molecule. Human and murine RBCs have been successfully loaded with
Zoledronate by a procedure of hypotonic dialysis and isotonic resealing, obtaining a dose-dependent drug entrapment with
a maximal loading of 7.9662.03, 6.9563.9 and 7.061.89 mmoles of Zoledronate/ml of packed RBCs for human, Swiss and
Balb/C murine RBCs, respectively. Engineered RBCs were able to detach human and murine macrophages in vitro, leading to
a detachment of 6668%, 6768% and 60.563.5% for human, Swiss and Balb/C RBCs, respectively. The in vivo efficacy of
loaded RBCs was tested in Balb/C mice administering 59 mg/mouse of RBC-encapsulated Zoledronate. By a single
administration, depletion of 29.0616.38% hepatic macrophages and of 67.8465.48% spleen macrophages was obtained,
confirming the ability of encapsulated Zoledronate to deplete macrophages in vivo. In conclusion, RBCs loaded with
Zoledronate should be considered a suitable system for targeted delivery to macrophages, both in vitro and in vivo.
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Introduction
Macrophages play a central role in the regulation of numerous
biological processes: maintenance of body homeostasis by remov-
ing senescent erythrocytes, apoptotic cells, macromolecules;
defense of host by ingesting and digesting microorganisms; control
of other cell activities by secretion of soluble molecules involved in
establishment of inflammatory responses. Unfortunately, as less
desirable consequences of their action, macrophages contribute to
the pathogenesis of diseases such as immunothrombocytopenia [1]
and autoimmune hemolytic anemia [2] by rapidly removing and
destructing autoimmune antibody-complexed blood constituents
and they also play a key role in the propagation of viruses in HIV-
1 and HSV-1 infections [3–4]. They are responsible for the
destruction of non-autologous grafted cells and materials [5] and
due to the release of proinflammatory cytokines, macrophages are
involved in harmful inflammatory reactions such as rheumatoid
arthritis [6] and sepsis [7]. Furthermore, recent studies focus on
macrophage role in inflammatory processes that occur in tumor
stroma and create favorable conditions for cancer progression [8].
In particular, a sub-type of macrophages recruited at tumor site(s),
the tumor associated macrophages (TAMs), are suggested to have
critical functions by promoting angiogenesis and metastasis,
suppressing adaptive immunity and expressing growth factors
and matrix proteases [9–10]. Therefore, transient suppression of
macrophage activities might be beneficial to patients and could
even be part of a therapeutic approach. A temporary decrease of
this cell lineage can be achieved by treatment with bisphospho-
nates (BPs), as shown in in vitro studies on macrophage-like cells
[11–17] and in in vivo studies both on tumor-bearing mice [18–22]
and in other pathologic conditions [23–29]. BPs are synthetic
analogues of pyrophosphate in which the P-O-P bridge has been
replaced by a non-hydrolysable P-C-P bond. The presence of a
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nitrogen atom in the R2 side chain divides them into two groups
with different intracellular mechanisms of action: non-amino
bisphosphonates or first generation bisphosphonates and amino
bisphosphonates, classified as bisphosphonates of second and third
generation, in which the nitrogen atom is enclosed in a
heterocyclic ring [30]. Due to their efficacy in inhibiting bone
resorption by osteoclasts, BPs are currently employed for the
treatment of musculo-skeletal diseases with high bone turnover
such as osteopenia [31], osteoporosis [32], hypercalcemia [33],
Paget’s syndrome [34], osteogenesis imperfecta [35] and bone
metastases [36]. Since macrophages belong to the same cell
lineage as osteoclasts and the latter represent the major targets of
BPs, their efficacy in affecting macrophages can be easily
understood. To be effective in macrophage depletion, bisphos-
phonates should be used at high doses because these molecules are
characterized by a short half-life in circulation, being rapidly
diverted to the bone or excreted unaltered by the kidneys with very
low extra-skeletal bioavailability. However, this exacerbates
toxicity problems such as nephrotoxicity, osteonecrosis of the jaws
and others already occurring at clinical doses [37–41] and makes it
necessary to protect bisphosphonates until their release and
intracellular accumulation in the target cells. For these reasons,
new formulations have been explored that are able to change
bisphosphonate pharmacokinetic profiles, prolong plasma half-life,
reduce bone accumulation and lower general toxicity. Until now,
liposome-encapsulated bisphosphonates (in particular, Clodro-
nate-loaded liposomes, such as Clodrolip [42,43]) have been
proposed for this purpose. Preclinical studies have shown the
efficacy of this treatment in the depletion of macrophages
associated with solid tumors (TAMs) [43], in the treatment of
tumors of macrophage origin [44], in the removal of circulating
monocytes for antinociceptive effects due to nerve damage [45], in
the removal of Kupffer cells involved in the onset of thrombocy-
topenic purpura [46] and in the onset of hemolytic anemia [47], as
examples of conditions in which the temporary elimination of
mononuclear phagocytes could have a clinical relevance. Howev-
er, such vehicles have reduced clinical application because of
limitations in production technologies [48] and experienced
toxicity in vivo [22,49]. An alternative to liposomes is the use of
erythrocytes, whose efficacy as carrier system has been extensively
documented in the last years [50–55]. Indeed, among the systems
used in drug delivery, RBCs have demonstrated a high potential as
drug carriers thanks to procedures inducing the opening of
nanopores on their surface which allow the entry of molecules
[53]. Furthermore, the possibility to modify the membrane surface
by promoting the formation of antigenic sites recognized by
macrophages allows the delivery of pharmaceutical molecules to
these cells [56,57]. Alternatively, lipophilic antibody-modified
RBCs could be developed to selectively reach the macrophages
[58,59]. Clodronate-loaded RBCs have already shown to be
effective in macrophage depletion both in vitro and in vivo
[57,60,61]. Given the growing interest in bisphosphonates for
their clinical potential, the present study aimed at identifying the
best performing bisphosphonate among Clodronate, Pamidronate,
Ibandronate and Zoledronate in causing detachment of adherent
human and murine macrophages and at evaluating the efficacy of
the selected drug loaded into RBCs in macrophage detachment in
in vitro studies compared to Clodrolip. Finally, engineered RBCs
have been successively investigated in Balb/C mice receiving
intravenous infusions of the selected bisphosphonate-loaded RBCs
for the depletion of liver and spleen macrophages.
Materials and Methods
Human blood samples
Human blood samples in heparinized vacutainers were
obtained from healthy volunteers included in the list of blood
donors from the Blood Transfusion Center of the Hospital ‘‘S.
Maria della Misericordia’’, Urbino (PU) Italy after signing a
written informed consent, under a protocol approved by the
Ethical Committee of the University of Urbino ‘‘Carlo Bo’’
(Protocol Number: 6589, approved on June 16th 2010).
Animals
Female Swiss and Balb/C mice were purchased from Charles
River Laboratories (Milan, Italy). Mice were kept under controlled
conditions at 2261uC, 12 h light/dark cycle, 6061% humidity
and 12 air changes/hour and provided with food and water ad
libitum. Healthy mice were at least 3 months old when used in
experiments. Use and care of the animals were approved by the
Ethical Committee of the University of Urbino ‘‘Carlo Bo’’
(Permit Number: CESA 1/2013, approved on February 06th 2013)
and all procedures were conducted in conformity with national
and European laws.
Reagents
Zoledronate used in in vitro experiments was kindly provided by
Novartis Pharma (Basel, Switzerland). Clodronate, Pamidronate,
Ibandronate were purchased from Sigma Aldrich (St. Louis, MO,
USA), as well as Zoledronate used in in vivo studies. The structure
of bisphosphonates is depicted in Figure 1. Bisphosphonate stock
solutions were prepared in distilled water, adjusted to pH 7.4 and
filter-sterilized prior to use. Empty liposomes and Clodrolip were
prepared as described before [43]. Other reagents were purchased
from Sigma Aldrich. All solutions were prepared in distilled water
and filter-sterilized prior to use.
Preparation of human and murine macrophages
Human monocyte-derived macrophages (M/M) from buffy-
coats of healthy adult blood donors were obtained by density
gradient separation using Lymphoprep solution (Axis-Shield PoC
Figure 1. Bisphosphonates. General structure A), Clodronate B),
Pamidronate C), Ibandronate D), Zoledronate E).
doi:10.1371/journal.pone.0101260.g001
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AS, Oslo) [57]. Monocytes were separated from lymphocytes by
adherence to tissue plastic dishes or to 96-wells plastic plates
(Sarstedt, Nu¨mbrecht, Germany), overnight at 37uC in a
humidified 5% CO2 atmosphere. Non adherent cells were
Figure 2. Effect of free bisphosphonates on human macrophage cultures. Count of adherent and non-adherent macrophages by Trypan
Blue staining after 48 h of continuous treatment with four different bisphosphonates at concentrations ranging from 0.25 to 1.0 mM A). MTS
evaluation of cell viability after 48 h and 6 days of continuous treatment with four different bisphosphonates at concentrations ranging from 0.25 to
1.0 mM B). Results are mean 6 SD of at least 3 experiments performed in duplicate. CTL = controls; Clo =Clodronate; Zol = Zoledronate;
Pam=Pamidronate; Iba = Ibandronate. *** p,0.001, **p,0.01 and *p,0.05 by ANOVA analysis with Bonferroni post-hoc test.
doi:10.1371/journal.pone.0101260.g002
Table 1. Zoledronate loading in Balb/C RBCs.
Dialysis time (min) mOsm at the end of dialysis mM Zol during incubation mmoles Zol/ml packed RBCs
120 125 20 0.1660.02
120 125 40 1.8860.07
120 125 60 2.4661.03
150 100 50 7.0061.89
The results are mean 6 SD of three experiments.
doi:10.1371/journal.pone.0101260.t001
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removed by repeated washes with RPMI-1640 medium. Human
monocyte-derived macrophages were cultured for seven days in
RPMI 1640 medium, supplemented with 10 U/ml penicillin,
10 mg/ml streptomycin, 2 mM L-glutamine and 10% heat-
inactivated fetal calf serum (Lonza, Milan, Italy) changed every
two days. On the seventh day of culture, adherent macrophages
were used for experiments. Macrophages (46105 per dish) were
used for the treatment with bisphosphonate-loaded vehicles or free
drug. Murine macrophages were collected from the peritoneum of
Swiss mice. Cold PBS (10 ml) containing 100 IU/ml penicillin,
100 mg/ml streptomycin and 5 IU/ml heparin was injected into
the abdominal cavity, the peritoneum was massaged and the
peritoneal fluid with the cell suspension was collected in sterile
centrifuge tubes. After centrifugation, cells were suspended in
completed RPMI 1640 medium and 56106 cells were placed in
culture tissue dishes and incubated for 12 h at 37uC in a 5% CO2
atmosphere. Peritoneal cells were gently washed with PBS several
times and treated with bisphosphonate-loaded vehicles or free
drugs.
Loading of Zoledronate in human and murine RBCs
Zoledronate was encapsulated in human RBCs by a procedure
of hypotonic dialysis, isotonic resealing and reannealing as
previously reported [62], with some modifications. Briefly, human
RBCs were washed in 10 mM Hepes (pH 7.4), containing
154 mM NaCl and 5 mM glucose, to remove leukocytes and
platelets. RBCs were resuspended at 40% hematocrit (Ht) in the
same washing buffer and dialyzed for 120 min against 50 volumes
of 10 mM NaH2PO4, 10 mM NaHCO3 and 20 mM glucose
(pH 7.4), containing 3 mM glutathione and 2 mM ATP (dialysis
buffer) using a tube with a cut-off of 12–14 kDa. The osmolality of
the buffer was about 60 mOsm, whereas the RBCs reached about
80 mOsm at the end of dialysis. All these procedures were
performed at 4uC. After this step, 50 mmol of drug were added to
each milliliter of dialyzed RBCs, which were then incubated for
30 min at room temperature under gentle mixing. Resealing of
RBCs was obtained by adding PIGPA (5 mM adenosine, 100 mM
inosine, 2 mM ATP, 100 mM MgCl2, 0.194 M NaCl, 1.606 M
KCl and 35 mM NaH2PO4, pH 7.4) in order to reestablish
isotonicity and incubating the resealed cells at 37uC for 25 min.
RBCs were washed three times with washing buffer and further
processed to increase their recognition by macrophages as
described below. As control, unloaded (UL) RBCs, i.e. RBCs
submitted to the loading procedure but without bisphosphonate
addition, in the in vitro experiments were used. To encapsulate the
drug in murine RBCs, blood was collected from CO2-anesthetized
Swiss and Balb/C mice by puncture of the retro-orbital sinus in
heparinized capillary tubes. Then the same procedure performed
Table 2. Mean corpuscular indexes of RBCs.
MCV (mm3) MCH (pg Hb/RBC) MCHC (g/dl)
Human NT 8765 3164 3663
Loaded 6867 23610 33611
Swiss NT 4661 1961 4161
Loaded 4268 1864 4261
Balb/C NT 4762 1660.3 3462
Loaded 3961 1561 3862
The results are mean 6 SD of three experiments. NT = not-treated RBCs.
doi:10.1371/journal.pone.0101260.t002
Figure 3. Effect of free and encapsulated bisphosphonates on human macrophage cultures. Count of adherent and non-adherent
macrophages by Trypan Blue staining after 48 h, 6 days and 14 days after removal of drugs. Results are mean 6 SD of at least 3 experiments
performed in duplicate. CTL = controls; Lip = empty liposomes; C-lip 0.01, 0.1 mM=Clodronate-liposomes at 0.01 and 0.1 mM concentration,
respectively; Zol 0.1 mM=Zoledronate at 0.1 mM concentration; UL =unloaded RBCs; L-Zol = RBCs loaded with Zoledronate to a final concentration
of 7.9662.03 mmoles/ml of packed RBCs. *** p,0.001, **p,0.01 and *p,0.05. by ANOVA analysis with Bonferroni post-hoc test.
doi:10.1371/journal.pone.0101260.g003
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for human RBCs was carried out, except that a different dialysis
buffer (15 mM NaH2PO4 and 15 mM NaHCO3 instead of
10 mM) and a different hematocrit (60% Ht) were used. At the
end of dialysis, Swiss and Balb/C RBCs reached about 100 and
125 mOsm, respectively (an extended dialysis up to 150 min was
subsequently needed for the reduction to 100 mOsm by Balb/C
RBCs, thus increasing loading efficiency). To load increasing
amounts of Zoledronate, dialyzed Swiss RBCs were incubated
with 10–25–50 mM Zoledronate, whereas dialyzed Balb/C RBCs
were incubated with 20–40–60 mM Zoledronate and processed as
previously described.
Targeting of Zoledronate-loaded RBCs to macrophages
Targeting of bisphosphonate-loaded RBCs to macrophages was
obtained essentially by promoting the formation of band 3 clusters,
which are recognized by the immune system as senescence
antigens [63] and consequently opsonized by autologous antibod-
ies. In detail, the loaded RBC suspension (10% Ht) was incubated
with 1.0 mM ZnCl2 and treated with 1.0 mM bis(sulfosuccinimi-
dyl)suberate (BS3) for 15 min at room temperature under gentle
mixing, then washed once with buffer containing 10 mM
ethanolamine (pH 7.4) and once with buffer containing 1% (w/
v) bovine serum albumine (BSA). RBCs were then incubated in
autologous plasma for 60 min at 37uC at a hematocrit of 20% to
induce IgG binding, followed by washing once with buffer
containing 2% (w/v) BSA and once with plain buffer. Unloaded
Figure 4. Effect of free and encapsulated bisphosphonates on Swiss mouse macrophage cultures. Count of adherent and non-adherent
macrophages by Trypan Blue staining after 1, 2 and 6 days after removal of drugs. Results are mean 6SD of at least 3 experiments performed in
duplicate. CTL = controls; Lip = empty liposomes; C-lip 0.01, 0.1 mM=Clodronate-liposomes at 0.01 and 0.1 mM concentration, respectively; Zol
0.1 mM=Zoledronate at 0.1 mM concentration; UL = unloaded RBCs; L-Zol = RBCs loaded with Zoledronate to a final concentration of 6.9563.9
mmoles/ml of packed RBCs. *** p,0.001, and **p,0.01 by ANOVA analysis with Bonferroni post-hoc test.
doi:10.1371/journal.pone.0101260.g004
Figure 5. Effect of free and encapsulated bisphosphonates on Balb/C mouse macrophage cultures. Count of adherent and non-adherent
macrophages by Trypan Blue staining after 1, 2 and 6 days after removal of drugs. Results are mean 6SD of 3 experiments. CTL = controls;
UL = unloaded RBCs; L-Zol = RBCs loaded with Zoledronate to a final concentration of 7.061.89 mmoles/ml of packed RBCs. **p,0.01 by ANOVA
analysis with Bonferroni post-hoc test.
doi:10.1371/journal.pone.0101260.g005
Macrophage Depletion by Bisphosphonates
PLOS ONE | www.plosone.org 5 June 2014 | Volume 9 | Issue 6 | e101260
RBCs underwent the same procedure. Zoledronate-loaded RBCs
were then added to macrophages (100:1 v/v ratio) and their ability
to detach cells from culture dishes was evaluated and compared to
control RBCs.
Assessment of haematological parameters
Red blood cell number, mean corpuscular volume (MCV),
mean corpuscular haemoglobin (MCH) and mean corpuscular
haemoglobin concentration (MCHC) were determined by a
haemocytometer (ABX MICROS, Horiba ABX SAS, Montpel-
lier, France) before and after the drug loading procedure.
Quantification of encapsulated-Zoledronate by LC-MS/
MS
The quantitative analysis of Zoledronate was performed by
Accelera S.r.l. (Nerviano, MI, Italy). To determine the amount of
bisphosphonate encapsulated into RBCs, an aliquot of opsonized
Zoledronate-loaded RBCs was resuspended at 10% Ht and
processed as reported by Veldboer K et al. [64], with some
modifications. Samples (50 ml) were transferred to an Eppendorf
tube and added with 100 ml of 10 mM ammonium bicarbonate.
After centrifugation at 2,060 g for 15 min, the supernatant was
transferred to a test tube and added with 700 ml of 10 mM
ammonium bicarbonate. A solid phase extraction (SPE) was used
to separate Zoledronate from matrix components and perform the
derivatization reaction. Anion-exchange cartridges (100 mg; Var-
ian, Palo Alto, CA, USA) were conditioned with 1 ml methanol
and 1 ml water. An aliquot of 700 ml of samples and calibration
standards was then flowed through the sorbent. Cartridges were
washed with 2 ml water and 1.5 ml methanol. After addition of
100 ml trimethylsilyl diazomethane (TMS-DAM, 2 M in hexanes)
the flow was stopped and methanol (750 ml) was added. After
1 hour at room temperature, the tube was opened and the solution
was collected. The cartridge was subsequently rinsed with
methanol (500 ml) and the obtained mixture evaporated to dryness
by nitrogen streaming at 40uC. The residue was reconstituted in
200 ml of a mixture of 10 mM ammonium acetate (pH 5.0) and
methanol (95:5, v/v). An aliquot of 15 ml was injected onto the
analytical column. The LC-MS/MS system consisted of a hybrid
triple quadrupole/linear ion trap 4000QTRAP (Applied Biosys-
tems/MDS SCIEX, Foster City, CA, USA) mass spectrometer
interfaced to a 1100 series HPLC pump (Agilent) and a CTC PAL
autosampler (CTC Analytics, Zwingen, Switzerland). A binary
gradient of mobile phase A (10 mM ammonium acetate, pH 5.0)
and mobile phase B (methanol) was applied for the chromato-
graphic separation. A Gemini C18 column (5062.0 mm, 5.0 mm;
Phenomenex, Castel Maggiore, Italy) was used. The analyte was
Figure 6. Effect of different Zoledronate concentrations in loaded erythrocytes on Swiss mouse macrophage cultures. Count of
adherent and non-adherent macrophages by Trypan Blue staining, 1, 2 and 6 days after removal of drugs. Results are mean 6SD of 3 experiments.
CTL = controls; UL = unloaded RBCs; L-Zol 1, 2, 3 = RBCs loaded with Zoledronate to a final concentration of 1.87, 3.36 and 5.57 mmoles/ml of packed
RBCs, respectively. *** p,0.001 and **p,0.01 by ANOVA analysis with Bonferroni post-hoc test.
doi:10.1371/journal.pone.0101260.g006
Table 3. Stability of Zoledronate loaded-RBCs.
Time 0 h 2 h 16 h 24 h
UL RBCsx106/ml 0.21 0.21 0.21 0.22
Ht 0.8 0.8 0.8 0.8
L-Zol 10 mM RBCsx106/ml 0.13 0.14 0.13 0.13
Ht 0.5 0.5 0.5 0.5
L-Zol 25 mM RBCsx106/ml 0.16 0.16 0.17 0.16
Ht 0.6 0.6 0.6 0.6
L-Zol 50 mM RBCsx106/ml 0.1 0.1 0.11 0.1
Ht 0.4 0.4 0.4 0.4
RBC count at different times of incubation after the loading procedure. RBCsx106/ml =millions of RBCs/ml; Ht = hematocrit; UL = unloaded RBCs; L-Zol 10, 25,
50 mM=RBCs incubated with 10, 25 and 50 mM of Zoledronate, respectively.
doi:10.1371/journal.pone.0101260.t003
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ionized with an ionspray voltage of 5200 V, using 40 psi nebulizer
and 40 psi heater gases at a temperature of 600uC. Detection was
performed by monitoring the transition 329.203 m/z in MRM
positive ion mode. The results were expressed as mmoles of
Zoledronate/ml of packed (100% Ht) RBCs.
Evaluation of macrophage detachment by Trypan Blue
count
Clodronate, Pamidronate, Ibandronate and Zoledronate were
added to human macrophage cultures at concentrations ranging
from 0.25 to 1.0 mM. After 48 h incubation at 37uC, detached
cells were collected and counted by Trypan Blue staining. The
cells still remaining adherent were removed by using a scraper and
counted. In subsequent experiments, human and murine macro-
Figure 7. Liver immunohistochemical examination. Healthy Balb/
C mice (n = 3) received intravenously 59 mg of Zoledronate by loaded
RBCs. Seven days post treatment the livers were removed and
processed by immunohistochemistry. Liver sections from control A)
and treated B) mice were incubated with anti-F4/80 antibody.
Magnification 406. The number of macrophages was evaluated
counting 10 randomly selected fields/slide and the results were
expressed as percentage in relation to untreated controls C). The
arrows point at some F4/80 positive macrophages. CTL= controls;
TR = treated mice. Control vs. treated mice, P,0.001 by unpaired t test
with Tukey post-hoc test.
doi:10.1371/journal.pone.0101260.g007
Figure 8. Spleen immunohistochemical examination. Healthy
Balb/C mice (n = 3) received intravenously 59 mg of Zoledronate by
loaded RBCs. Seven days post treatment, the spleens were removed
and processed by immunohistochemistry. Spleen sections from control
A) and treated B) mice were incubated with anti-F4/80 antibody.
Magnification 406. The number of macrophages was evaluated
counting 10 randomly selected fields/slide and the results were
expressed as percentage respect to untreated controls C). The arrows
point at positive zones. CTL = controls; TR = treated mice. Control vs.
treated mice, P,0.001 by unpaired t test with Tukey post-hoc test.
doi:10.1371/journal.pone.0101260.g008
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phages were treated overnight (16 h) with Zoledronate-loaded
RBCs at a ratio of 100 RBCs per macrophage. After incubation,
dishes were gently washed with culture medium several times to
remove the non-phagocytized RBCs. Exhausted medium was
replaced and the incubation continued. At different times,
macrophages were processed as above and the percentage of
adherent cells compared to total adherent plus detached cells was
calculated. UL RBCs, free drug, empty liposomes and Clodrolip
were administered as controls.
Evaluation of macrophage viability by MTS assay
The ability of viable human macrophages to reduce the MTS
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-
fophenyl)-2H-tetrazolium] reagent was also assessed following
treatment with the free bisphosphonates Clodronate, Pamidro-
nate, Ibandronate and Zoledronate at concentrations ranging
from 0.25 to 1.0 mM. In detail, after incubation of macrophages
with BPs for 2 and 6 days the drugs were removed by repeated
washings with PBS. MTS (0.4 mg/ml) reagent was added to each
well and plates were placed at 37uC for 3 h. The absorbance was
measured at 490 nm using a Microplate Reader (Bio-Rad,
Segrate, Italy). Results are expressed as percentage of cell viability
in respect to control cells.
Stability of Zoledronate-loaded RBCs
In order to evaluate the stability of RBCs after the loading
procedure and the ability to retain the encapsulated drugs, an
RBC count was performed at different times (0–2-16–24 h) of
incubation. In detail, Swiss mouse erythrocytes loaded with
different amounts of Zoledronate were dispensed in 35 mm
diameter dishes in complete RPMI medium at Hts ranging from
0.4 to 0.8% and incubated at 37uC. At scheduled times, the dishes
were gently agitated to resuspend the cells and the number of
RBCs was determined. Each condition was analysed in duplicate.
Furthermore, after 16 h of incubation, the amount of drug inside
the RBCs was quantified by LC-MS/MS analysis.
In vivo experiments
Balb/C mice 8 weeks old and of 22–24 g body weight, were
used. The ability of Zoledronate-loaded RBCs to deplete
macrophages in vivo was assessed in healthy mice. Mice (n = 3)
were injected intravenously (i.v.) with 200 ml of Zoledronate-
loaded RBCs at 12.5% Ht and sacrificed after 7 days. Spleen and
liver were removed and total numbers of macrophages were
counted by immunohistochemistry.
Tissue processing
The explanted organs were immediately processed according to
the following protocol: fresh specimens were fixed in buffered 4%
formaldehyde for 14–16 hours and dehydrated by increasing
gradients of ethanol. Samples were then degreased twice in xylene
and embedded in paraffin at 58uC. Semi-thin sections (3 mm) were
produced with a rotary microtome (TOP Rotary S-130, Pabisch,
Milan, Italy).
Immunohistochemistry
The sections were deparaffinized twice in xylene and rehydrated
in a descending ethanol series. After removal of the embedding
material, endogenous peroxidases were blocked with 3% H2O2,
30% methanol in Tris-buffered saline (TBS, pH 7.4). Then,
sections were rinsed in TBS, incubated in buffered citrate solution
(pH 5.9) for 30 min at 96uC and rinsed with TBS. Unspecific
binding was blocked with 20% normal goat serum (Millipore,
Billerica, MA, USA). Rat anti-mouse antibody against F4/80
(AbD Serotec, Bio-Rad) was diluted 1:100 in TBS plus 2% (w/v)
BSA and used as primary antibody, to detect total macrophages.
Primary antibody was incubated over night at 4uC, followed by the
secondary goat anti-rat horseradish peroxidase-conjugated anti-
body (AbD Serotec) which was incubated for 1 h at room
temperature. Diaminobenzidine was used as final chromogen.
Sections were counterstained with haematoxylin for 7 min.
Sections were dehydrated through a graded alcohol series,
degreased and mounted in Eukitt. Tissue samples were observed
at 406magnification to identify positive cells. F4/80 positive cells
were counted in 10 randomly chosen fields/slide. As negative
control, the staining procedures were carried out without primary
antibody, whereas rat IgGs were used as isotype control. No
immunoreactivity was observed in both conditions. The sections
were also haematoxylin and eosin (H&E) stained, to check the
general morphology of specimens.
Statistical analysis
Data are presented as Mean 6 Standard Deviation (SD).
Statistical comparisons were performed by one-way analysis of
variance (ANOVA) with Bonferroni post-hoc test, for multiple
comparisons, or by unpaired t test with Tukey post-hoc test, for
comparisons between two groups. Differences were considered
significant at P values ,0.05.
Results
Identification of the most efficient bisphophonate
To identify the most efficient bisphosphonate able to detach
macrophages Clodronate, Pamidronate, Ibandronate and Zole-
dronate were administered for 48 h to human macrophage
cultures at concentrations ranging from 0.25 to 1.0 mM. A
dose-dependent detachment was obtained (Fig. 2a) reaching
7168% by Clodronate, 4569% by Pamidronate, 1865% by
Ibandronate and 5068% by Zoledronate at 1.0 mM BP. In MTS
cytotoxicity experiments, the viability after 48 h treatment was
4968% for Clodronate, 7367% for Pamidronate, 79610% for
Ibandronate and 5068% for Zoledronate (Fig. 2b). The MTS
evaluation was further prolonged up to 6 days, assessing a vitality
of 24610% for Clodronate and 862% for Zoledronate (Fig. 2b).
On the basis of the overall results, Zoledronate was chosen as
reference drug in subsequent tests, aimed at evaluating the ability
of RBC-encapsulated bisphosphonates to detach macrophages.
Loading and quantification of Zoledronate in human and
murine RBCs
Zoledronate loading was carried out both in human and in
murine RBCs. Zoledronate was encapsulated by a procedure of
hypotonic dialysis and isotonic resealing as described above. The
quantification of the intra-cellular drug concentration, evaluated
after the loading and opsonization phase, was made by LC-MS/
MS analysis, resulting in 7.9662.03 and 6.9563.9 mmoles of
Zoledronate/ml of packed RBCs in human and Swiss RBCs,
respectively. Furthermore, varying the amount of drug added to
dialyzed Swiss mouse RBCs (10, 25, and 50 mM Zoledronate)
increasing encapsulation was obtained resulting in 1.87, 3.36 and
5.57 mmoles Zoledronate/ml of packed RBCs, respectively.
Since the in vivo efficacy of encapsulated Zoledronate was tested
in Balb/C mice, the loading experiments were optimized in Balb/
C RBCs. Balb/C RBCs were dialyzed against the hypotonic buffer
for 120 min and successively incubated with different amounts of
drug (20, 40 and 60 mM Zoledronate), obtaining an increasing
encapsulation rate of 0.1660.02, 1.8860.07 and 2.4661.03
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mmoles Zoledronate/ml of packed RBCs, respectively, which was
lower than that observed in Swiss mouse erythrocytes. This result
is probably due to the higher cell osmolarity obtained at the end of
the dialysis step in Balb/C RBCs (125 mOsm), compared to the
Swiss cells (100 mOsm). To increase the extent of encapsulated
drug, the dialysis was prolonged up to 150 min, reaching an
osmolarity value comparable to Swiss RBCs (100 mOsm).
Incubating these RBCs with 50 mM of Zoledronate, correspond-
ing to the highest drug concentration that allows to remain below
150 mOsm (limit of osmolarity at which the transient membrane
pores are opened) a loading of 7.061.89 mmoles Zoledronate/ml
of packed RBCs was achieved. The results of loading of Balb/C
RBCs are summarized in Table 1.
Evaluation of human and murine hematological
parameters
For all loading experiments, the assessment of mean corpuscular
indices of loaded RBCs was performed. The mean cell volume
(MCV), the mean hemoglobin content and concentration (MCH
and MCHC) of RBCs from untreated blood (NT) were compared
to those of human and murine cells submitted to the loading
procedure. The results summarized in Table 2 show that the
dialysis process in hypotonic medium led to a reduction of cell
volume and to a decrease in hemoglobin content. For human
RBCs, the reduction was more consistent, whereas for murine
RBCs the differences in respect to untreated cells were less
pronounced, evidencing a minor susceptibility of murine RBCs to
membrane modifications. Moreover, at the end of the loading
procedure, Balb/C RBCs presented a lower MCV than Swiss
mouse RBCs.
Efficacy of human Zoledronate-loaded RBCs in
macrophage detachment
Human RBCs loaded with Zoledronate to a final concentration
of 7.9662.03 mmoles/ml of packed RBCs were administered
overnight to cultured human macrophages. At different times after
RBC removal (2, 6 and 14 days), the percentages of macrophages
adherent to plastic dishes were evaluated (Fig. 3). The results show
that a single administration of Zoledronate-loaded RBCs is able to
significantly detach macrophages in a time-dependent manner
leading to 6668% of cell detachment after 14 days treatment.
When UL RBCs were administered, 2964% of detached cells was
observed and 20611% for controls, respectively. On day 14, a
significant reduction in adhesion ability following free Zoledronate
(74611%) administration was observed. The number of detached
macrophages after treatment with different amounts of empty
liposomes and Clodrolip was also evaluated. As expected, the
extent of detachment was time- and concentration- dependent,
confirming results previously reported by van Rojien N et al. [65].
After 14 days treatment with 0.1 mM Clodrolip 75613% of
macrophages lost adhesion. However, addition of 0.1 mM empty
liposomes caused a detachment of 46613%.
Evaluation of murine macrophage detachment
The ability of murine bisphosphonate-loaded RBCs to reduce
the number of plastic-adherent peritoneal macrophages was
evaluated. Swiss mouse RBCs containing 6.9563.9 mmoles
Zoledronate/ml of packed RBCs were added overnight to murine
peritoneal macrophages and the number of adherent macrophages
was evaluated after 1, 2 and 6 days. Clodrolip was also
administered and as controls UL RBCs, empty liposomes and
free Zoledronate were used. As shown in Figure 4, the loss of cell
adhesion was concentration- and time-dependent for all tested
conditions. It should be noted that macrophages treated with
Zoledronate-loaded RBCs showed a significant and marked
detachment already after 24 h, highlighting the effectiveness of
Zoledronate-loaded RBCs. The highest macrophage detachment
was observed 6 days after administration of encapsulated Zole-
dronate when 6766% cell detachment was reached. When free
Zoledronate was used, the adherence of macrophages to plastic
dishes was affected to a lesser extent and 4868% detachment was
obtained at 0.1 mM concentration. A good activity was also seen
with 0.1 mM Clodrolip with 5266% detachment. By administer-
ing UL RBCs only 1364% detachment was observed, a value
slightly higher than that registered with untreated control
macrophages (965%). Six days after RBC removal similar results
were obtained with Zoledronate encapsulated in Balb/C RBCs at
a final concentration of 7.061.89 mmoles/ml of packed RBCs
(Fig. 5). Starting from this evidence, to better characterize the
effect of engineered RBCs, macrophage detachment after admin-
istration of RBCs loaded with increasing amounts of Zoledronate
(1.87, 3.36, and 5.57 mmoles/ml of packed RBCs) was evaluated in
Swiss mouse macrophages. The results (Fig. 6) showed that by
increasing the concentration of added drug, the ability of
Zoledronate-loaded RBCs to promote detachment increased as
well. This result was particularly evident 1 and 2 days after
removal of RBCs, while after 6 days the difference was less
pronounced.
Stability of Zoledronate-loaded RBCs
To evaluate a possible loss of drug due to cell lysis, a stability test
was carried out on Swiss mouse RBCs loaded with different
amounts of Zoledronate (1.87, 3.36 and 5.57 mmoles/ml of packed
RBCs) by counting, as an indirect evaluation of hemolysis, the
number of intact RBCs during 0–24 h incubation. The results
reported in Table 3 highlight that at increasing incubation times
(0–2–16–24 h) no change in erythrocyte number following the
loading procedure could be detected, suggesting that the drug was
essentially retained by the loaded cells. This result was confirmed
by the quantification of intracellular Zoledronate: after 16 h of
incubation (time during which phagocytosis of Zoledronate-loaded
RBCs was allowed), 103615% of loaded drug was detected inside
the RBCs. Moreover, the different amounts of encapsulated drug
did not modify RBC stability, compared to UL RBCs, showing no
effect of Zoledronate on RBC integrity.
In vivo experiments
To determine the in vivo effectiveness, Zoledronate-loaded
RBCs were infused in healthy mice receiving i.v. 200 ml of RBC
suspension at 12.5% Ht (corresponding to 59 mg Zoledronate).
Seven days after treatment, mice were sacrificed. Spleen and liver
were removed and paraffined sections were prepared as described.
Sections were stained by immunohistochemical techniques to
reveal total tissue macrophages and F4/80 positive cells were
counted in 10 randomly chosen fields/slide. By a single
Zoledronate-loaded RBC administration, a significant reduction
of 29.0616.38% (P,0.001) in hepatic macrophages (Fig. 7) and of
67.8465.48% (P,0.001) in spleen macrophages (Fig. 8) was
obtained, compared to untreated controls, thus confirming the
ability of encapsulated Zoledronate to deplete macrophages.
Discussion
Transient macrophage depletion could be a valid approach for
the treatment of several clinical pathologies and literature data
[11–29] suggest that bisphosphonates are suitable to reach this
goal. Until now, liposome-encapsulated Clodronate has docu-
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mented its efficacy in vitro and in preclinical investigations for the
transient suppression of macrophage functions [42,43]. However,
liposome technology shows some limitations linked to industrial
applicability [48] and toxic effects in mice [22,49]. Thus, a safe
delivery system to selectively target bisphosphonates to macro-
phages is still needed and an alternative approach could be
represented by the use of autologous engineered RBCs. In fact, an
abundant literature [see reviews 50–55] demonstrates that RBCs
present unique features that make them ideal vehicles for drug
delivery. They are readily available in large quantities, biocom-
patible when autologous RBCs are used, and completely
biodegradable. They also have a prolonged life span in circulation,
possess a great ability to retain encapsulated drugs and they can be
loaded with a variety of molecules. Furthermore, the morpholog-
ical, immunological and biochemical properties of loaded RBCs
are similar to those of native cells. Thus, they can be used as
carriers for sustained drug release or for targeted delivery to
macrophages by exploiting their natural fate.
Our first aim was to identify the best performing bisphospho-
nate among Clodronate, Pamidronate, Ibandronate and Zoledro-
nate in inducing cell detachment and death in primary human
macrophage cultures, in order to select the best compound to
encapsulate into RBCs. To this end, both the effect on cell
adhesion and the effect on cell viability were evaluated.
Clodronate, Pamidronate and Zoledronate have shown to
significantly decrease the ability of macrophages to adhere to
plastic dishes. Zoledronate appeared to be the most active
molecule in reducing macrophage viability at all tested concen-
trations and thus it was the drug of choice for the RBC loading
experiments. Since Zoledronate is a non-diffusible highly nega-
tively charged molecule, it can easily be loaded into erythrocytes
through a procedure which causes a transitory opening of pores in
the RBC membranes, enabling Zoledronate to remain confined
within the cells once pores are resealed. It is worth mentioning that
the results discussed here are from Zoledronate-loaded RBCs
obtained by a manual loading procedure based on hypotonic
hemolysis, as usually done when small volumes (,10 ml) of blood
are available. Zoledronate-loaded RBCs were modified by
induction of Band 3 clusters in order to produce cells that could
be phagocytized by macrophages. A similar approach has already
been used to develop Clodronate-loaded RBCs, whose efficacy in
depleting macrophages had been observed both in in vitro and
in vivo studies [57,60,61]. Since our comparative data with BPs
administered as free drugs showed that Zoledronate was more
efficient than Clodronate, the ability of Zoledronate-loaded RBCs
to detach or deplete macrophages was tested both in vitro and
in vivo. In addition, it is also important to point out that
Zoledronate is a latest generation bisphosphonate with numerous
clinical applications. In particular, growing interest comes from its
use as anti-neoplastic agent able to induce apoptosis in TAMs and
to induce their repolarization to a tumor-fighting phenotype [19],
thus proving to be a drug of great therapeutic interest.
Therefore, the number of human monocyte-derived macro-
phages remaining adherent to plastic culture dishes, at different
incubation times following treatments with Zoledronate-loaded
RBCs, was determined. The results showed that a single overnight
(16 h) administration of RBCs was able to significantly reduce in a
time-dependent manner the cell’s ability to adhere, reaching
6668% macrophage detachment 14 days post treatment. This
result was higher than that obtained with Clodronate-loaded
erythrocytes (3966%), prepared following the same procedure
used to encapsulate Zoledronate, confirming previous work (data
not shown) [54]. Moreover, it is noteworthy that by administering
cells loaded with 7.9662.03 mmoles of Zoledronate/ml of packed
RBCs an intra-macrophage bisphosphonate concentration of
approximately 0.15 mM can be expected, considering that on
average 1.2 RBCs per macrophage were phagocytized [62]. When
0.1 mM of free Zoledronate was added as control, reduced
adhesion ability of macrophages was also observed at a level
comparable to that obtained using engineered RBCs. Neverthe-
less, it should be emphasized that this compound, because of its
toxicity and serious side effects, cannot be administered as free
drug in the clinic at the elevated concentrations utilized in this
study. In fact, the dosage for Zoledronate for the treatment of bone
metastases is 4 mg administered intravenously every 3–4 weeks,
corresponding approximately to a peak serum concentration of
1.41 mM [66]. Clodrolip administration again confirmed its
efficacy in macrophage detachment, showing results comparable
to those obtained by Zoledronate-loaded RBCs.
Since the following step was to test in vivo the ability of such
engineered RBCs to promote spleen and liver macrophage
depletion, similar experiments were also performed using perito-
neal murine macrophage cultures. At first, in vitro experiments
were carried out in RBCs isolated from Swiss mice, obtaining
results comparable to experiments with human RBCs loaded with
drug.
Finally, with the aim to test this proposed biotechnological
approach in a preclinical Balb/C murine model of pathologies
which could benefit from transient macrophage depletion, the
effect of Zoledronate-loaded RBCs has also been confirmed both
in vitro, using peritoneal macrophages from Balb/C mice, and
in vivo in the same murine strain. With regard to the in vivo results,
a marked reduction of spleen macrophages (67.8465.48%),
compared to untreated animals, was observed by immunohisto-
chemical analysis 7 days after administration of erythrocytes,
highlighting the in vivo validity of this approach. It is noteworthy
that this depletion was obtained following the administration of
only 59 mg/mouse of Zoledronate by loaded RBCs and that it was
similar to the effect previously reported in C57BL/6 mice [57] in
which 220 mg of encapsulated Clodronate were administered, thus
confirming the higher efficiency of our selected BP in in vivo
macrophage depletion. Instead, a macrophage depletion of
29.0616.38% was reached in hepatic tissue. This result was in
line to results previously observed with Zoledronate-liposomes for
which the highest uptake was recorded in spleen, followed by liver
[49]. The phenomenon is probably due to physiology of the liver.
Indeed, this organ is mainly supplied by portal vein which
transports the blood refluent from the spleen. Thus, loaded
erythrocytes, once i.v. injected, reach mostly the spleen where they
are phagocytized by resident macrophages. Such blood, poor in
loaded erythrocytes, subsequently flows to the liver through portal
vein. Therefore less erythrocytes are available to deplete hepatic
phagocytes.
In conclusion, this work represents one of few studies on
bisphosphonate-induced detachment conducted on primary hu-
man and murine macrophage cultures and demonstrates that,
among Clodronate, Pamidronate, Ibandronate and Zoledronate,
the latter is the most active bisphosphonate and RBCs loaded with
Zoledronate can be effective in the detachment and depletion of
macrophages both in vitro and in vivo. The transient suppression of
macrophage functions by employing Zoledronate-loaded RBCs
could play an important role in various research applications and
many biomedical phenomena with a high clinical potential.
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